Introduction to the 76-page Executive Informational Overview (EIO) for Amarantus BioScience Holdings, Inc. (AMBS-OTC)

.

• New 76-page Executive Informational Overview® (EIO) by Crystal Research Associates available on Amarantus BioScience Holdings, Inc. (AMBS-OTC) at www.crystalra.com

o Company developing diagnostics and therapeutics to treat diseases related to neurodegeneration and abnormal apoptosis (cell death); initial focus is Alzheimer’s disease (AD) and Parkinson’s disease (PD)

o Amarantus’ LymPro Test® is a unique blood diagnostic for AD to launch initially in 4Q14 as Laboratory Developed Test

o Eltoprazine is a therapeutic targeting side effects of existing PD treatments (Levodopa-Induced Dyskinesia [PD-LID]), expected to enter Phase 2b during 2014

o MANF is a preclinical therapeutic protein being developed for Retinitis Pigmentosa (RP) and other orphan diseases

Crystal Research Associates Presents: New Independent Equity Research

.

• Crystal clear, comprehensive report on a company in a manner that is easily understood by the Wall Street financial community

• Product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other fundamental information are detailed

• Free of investment ratings, target prices, and forward-looking financial models

• Complete risks and disclosures

• Written exclusively by experienced, award-winning analysts

What is an EIO?

.

Overview of Amarantus BioScience Holdings, Inc. (AMBS-OTC)

• Developing diagnostics and therapeutics for diseases linked to neurodegeneration and abnormal apoptosis; initial focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD)

• Pipeline includes an exclusive worldwide license to the Lymphocyte Proliferation Test (the LymPro Test®), a blood diagnostic for AD that could be the first of its kind to reach the market; and a license to Eltoprazine, a Phase 2b-ready therapeutic to treat debilitating side effects of existing PD treatment, Levodopa

• Company also building global intellectual property position around Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a therapeutic protein with potential in orphan diseases (Retinitis Pigmentosa [RP] as well as PD, AD, Wolfram’s Syndrome, diabetes, and ischemic heart disease)

• Company is Founding Member of the Coalition for Concussion Treatment (#C4CT), a program initiated in collaboration with Brewer Sports International to raise awareness of treatments in development for concussions and nervous system disorders

• Amarantus is located at Janssen Labs @QB3, a subsidiary of Johnson & Johnson that acts as an incubator for companies of interest to J&J’s core positions

• Roughly 5.4 mm U.S. individuals suffer from AD and over 500,000 are newly diagnosed each year (one in eight older Americans), with it being the third leading cause of death

• Costs for AD are likely to exceed $1.4 trillion by 2050

• Being able to differentiate individuals with AD early on is a critical component in the diagnostic process as AD trials have a history of patient recruitment errors stemming from inaccurate dementia diagnoses

• The LymPro Test®’s U.S. market opportunity could surpass $500 million/year

• Eltoprazine’s Phase 2b trial for PD-LID patients could commence in 2014

• Another candidate, Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), is a therapeutic protein with potential in orphan diseases

.

Overview of Amarantus BioScience Holdings, Inc. (AMBS-OTC)

The LymPro Test®

• Roughly 5.4 mm U.S. individuals suffer from AD and over 500,000 are newly diagnosed each year (one in eight older Americans), with it being the third leading cause of death

• Costs for AD are likely to exceed $1.4 trillion by 2050

• Being able to differentiate individuals with AD early on is a critical component in the diagnostic process as AD trials have a history of patient recruitment errors stemming from inaccurate dementia diagnoses

Eltoprazine

• At least four million people worldwide have PD, with 35% exhibiting symptoms of LID after three or more years of treatment with levodopa

MANF

• RP is a genetic degenerative disorder of the eye that starts in adolescence and makes people blind by the time they reach age 40; about 100,000 individuals in the U.S. and a comparable number in the EU are affected, which qualifies it as an orphan indication

.

Pipeline of Amarantus BioScience Holdings, Inc. (AMBS-OTC)

CANDIDATE INDICATION PRECLINICAL IND PHASE 1 PHASE 2A PHASE 2B PHASE 3

LymPro Alzheimer's

NuroPro Parkinson's Disease

LymPro TBI / CTE

Eltoprazine Parkinson's LID

Eltoprazine ADHD

MANF Retinitis Pigmentosa

MANF Parkinson's Disease

MANF TBI / CTE

DIAGNOSTICS DIVISION

THERAPEUTICS DIVISION

Creating a portfolio across multiple indications and sectors to mitigate risk and leave significant upside

potential

.

Amarantus BioScience Holdings, Inc. (AMBS-OTC)

"The scientific community and the FDA believe that it is critical to identify and study patients with very early

Alzheimer's disease before there is too much irreversible injury to the brain….It is in this population that most

researchers believe that new drugs have the best chance of providing meaningful benefit to patients."

- Russell Katz, MD, Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research

.

Corporate

• Listing common shares on a national stock exchange (e.g., NASDAQ or NYSE)

• Working to establish appropriate channels for scientific and clinical development, and for financial partnerships that could provide near- and long-term value creation across multiple fronts

The LymPro Test®

• Clinical performance data (3Q-14)

• Clinical performance studies to support CLIA registration (2H-14)

• Analytical performance package to support CLIA launch (4Q-14)

• CLIA submission (4Q-14)

• CLIA launch (4Q-14)

• Potential partnership agreement after the completion of the LP-002 study

Potential Milestones for Amarantus BioScience Holdings, Inc.

(AMBS-OTC)

.

Eltoprazine

• Initiate Phase 2b clinical trial for PD-LID (4Q-14)

MANF

• Functional genetic mouse model for Retinitis Pigmentosa (RP) (2H-14)

• Filing of Orphan Drug Designation (ODD) in RP (4Q-14)

• Wolfram’s Syndrome Retinal Data (4Q-14)

• Convection enhanced delivery (CED) data with Renishaw plc (a global company with core skills in measurement, motion control, spectroscopy, and precision machining) in PD (4Q-14)

• Preliminary systemic toxicology (4Q-14)

• Initiate Good Manufacturing Practices (GMP) manufacturing to prepare for first-in-man studies (4Q-14)

Potential Milestones (cont.)of Amarantus BioScience Holdings, Inc.

(AMBS-OTC)

.

• Gerald E. Commissiong, President & CEO—Led acquisition of diagnostic assets and MANF strategic development; Stanford University (Management Science & Engineering)

• Kerry Segal, Head of Business Development—VP Business Development at Impax Pharmaceuticals; Senior Director Global Business Development at Valeant Pharmaceuticals

• David A. Lowe, PhD, Board Member / Therapeutics—President & CEO at NeuroAssets, Sarl (retained to lead MANF product Development); Head of CNS R&D at Roche, Novartis & Sandoz (now Bayer)

• Adam J. Simon, PhD, Corporate Advisor / Diagnostics—President & CEO of Cerora, Inc.; Senior Research Fellow, Worldwide Alzheimer’s Biomarker Discovery at Merck

• Joseph Rubinfeld, PhD, Corporate Advisor—Co-founder of Amgen, Inc.; Inventor of Amoxycillin and other marketed drugs

Management

.

To read the entire 76-page EIO on Amarantus BioScience Holdings, Inc. (AMBS-OTC)

or find information on other companies under coverage, please visit www.crystalra.com.

.

Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has provided institutional-quality research on small- and mid-cap companies for the past decade. We are led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

About Us

Corporate Headquarters:880 Third Avenue, 6th FloorNew York, NY 10022Office: (212) 851-6685Fax: (609) 395-9339

Satellite Office Location:2500 Quantum Lakes Drive, Suite 203Boynton Beach, FL 33426Office: (561) 542-6903Fax: (561) 853-2246

Jeffrey J. Kraws,Chief Executive Officer

Karen B. GoldfarbPresident & COO

.

FACEBOOK — https://www.facebook.com/CrystalResearchAssociates

TWITTER — http://twitter.com/crystalresearch

YOUTUBE — https://www.youtube.com/user/crystalrsch

LINKEDIN — http://www.linkedin.com/company/crystal-research-associates

SLIDESHARE — http://www.slideshare.net/crystalresearchassociates

Connect with Crystal Research Associates